Randomized trial identifies active compounds in Pinus yunnanensis cones relating to breast cancer mechanisms, suggesting their potential in drug development.
Key Points
This research aims to identify bioactive compounds in Pinus yunnanensis cones and explore their mechanisms against breast cancer.
Developed an optimized UHPLC–MS/MS method for component analysis.
Identified 16 and 12 systemically absorbed components in rat plasma and feces, respectively.
Utilized network pharmacology and molecular docking to predict core targets and pathways.
Identified core components include coniferaldehyde and phyllanflexoid A targeting TP53, STAT3, and PIK3CA.
Key pathways involve VEGF signaling and PD-L1/PD-1 checkpoint in cancer.
Established a UHPLC–MS/MS platform for quality control and insights into anti-breast cancer drug development.